ADPT

Fred Alger Management, an investment management company, released its third-quarter 2026 investor letter for “Alger Small Cap Growth Fund”. The letter can be downloaded here.

Adaptive Biotechnologies now sits on a higher modeled fair value, with the price target moving from US$26.36 to US$28.31 per share.

Adaptive Biotechnologies has seen its share price move sharply in recent years, and the question now is whether the cash flows the business can generate really back up that kind of ride.

Adaptive highlights the role of MRD in the new consensus definition of cure in multiple myeloma, presented at the IMS 23rd Annual Meeting.

Adaptive Biotechnologies (ADPT) is back in focus after the National Comprehensive Cancer Network updated multiple myeloma guidelines to more fully embed minimal residual disease testing and explicitly reference the company’s clonoSEQ assay.

Adaptive Biotechnologies recently highlighted updates to the National Comprehensive Cancer Network multiple myeloma guidelines, which now feature a dedicated page on minimal residual disease testing and specifically reference its FDA-cleared clonoSEQ assay with preferred high-sensitivity thresholds and expanded testing timepoints.

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) highlighted updated National Comprehensive Cancer Network, or NCCN, multiple myeloma guidelines on September 17.

Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey

SEATTLE, Sept.

Adaptive Biotechnologies (ADPT) has surged 100% over the past year, driven by strong technical momentum. Shares recently hit a new 3-year high. Analyst sentiment is mixed with price targets ranging from $17 to $30.